294 related articles for article (PubMed ID: 34561115)
1. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
3. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
4. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
6. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
[TBL] [Abstract][Full Text] [Related]
7. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
8. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
9. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
[TBL] [Abstract][Full Text] [Related]
10. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():19-34. PubMed ID: 29600357
[TBL] [Abstract][Full Text] [Related]
12. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.
Coimbra FJF; de Jesus VHF; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Felismino T; Mello CAL; Almeida MF; Begnami MDFS; Dias-Neto E; Riechelmann RSP; da Costa WL
Ann Surg Oncol; 2019 Oct; 26(11):3618-3626. PubMed ID: 31222685
[TBL] [Abstract][Full Text] [Related]
13. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
[TBL] [Abstract][Full Text] [Related]
15. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
[TBL] [Abstract][Full Text] [Related]
16. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
Chen J; Wang A; Ji K; Bu Z; Ji J
BMC Cancer; 2020 Aug; 20(1):777. PubMed ID: 32811471
[TBL] [Abstract][Full Text] [Related]
17. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
18. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Newman E; Potmesil M; Ryan T; Marcus S; Hiotis S; Yee H; Norwood B; Wendell M; Muggia F; Hochster H
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S97-100. PubMed ID: 16399443
[TBL] [Abstract][Full Text] [Related]
20. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
Blank S; Lordick F; Bader F; Burian M; Dobritz M; Grenacher L; Becker K; Weichert W; Langer R; Sisic L; Stange A; Jäger D; Büchler M; Bruckner T; Siewert J; Ott K
Gastric Cancer; 2015 Apr; 18(2):314-25. PubMed ID: 24722800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]